<DOC>
	<DOC>NCT00309517</DOC>
	<brief_summary>This clinical investigation examined the influence of preoperative radiotherapy in combination with postoperative 5-fluorouracil + leucovorin chemotherapy vs. 5-fluorouracil + leucovorin + MAb 17-1A chemo-immunotherapy on patientsâ€™ local recurrence rate and overall survival time following surgery for rectal carcinoma Dukes B or C (T2-4, N0-3, M0).</brief_summary>
	<brief_title>Randomized Study on Neoadjuvant Radio-Chemotherapy in Rectal Carcinoma Dukes B and C</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<criteria>Patients with histologically verified operable rectal cancer Dukes B and C (Stage II, T24, N03, M0), R0 Age: 1880 years Karnofsky Performance Status &gt; 80 Adequate bone marrow reserve (leukocytes &gt; 4,000, thrombocytes &gt; 105/mm3, Hb &gt; 10g %), renal and hepatic functions (total bilirubin and creatinine &lt; 1.25 x ULN) Colon cancer R1, R2; carcinosis peritonei Start of treatment &gt; 42 days postop; other adjuvant radiotherapy, chemotherapy or immunotherapy Previous application of a murine or chimeric monoclonal antibody or antibody fragment Medical therapy with steroids, cyclosporin or antithymocyte globulin within 3 months prestudy Known hypersensitivity to animal protein Serious concomitant disease: HIV, chronically inflammatory intestine, diabetes mell. gravis, cerebral seizure disorder, et al. Pregnancy or lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2000</verification_date>
	<keyword>Fluorouracil</keyword>
	<keyword>Leucovorin</keyword>
	<keyword>MAb 17-1A</keyword>
	<keyword>Rectal cancer</keyword>
</DOC>